Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Astrocytoma 3Recurrence 2Prostatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Intestine Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Paranasal Sinus Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neurofibroma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neurilemmoma 1Neoplasms, Unknown Primary 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Mesothelioma, Malignant 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Recurrence × antineoplaston AS 2-1 × Clear all
NCT00003471 2018-03-22

Antineoplaston Therapy in Treating Patients With Low-Grade Astrocytoma

Burzynski Research Institute

Phase 2 Terminated
7 enrolled 6 charts
CNS

Astrocytoma, Recurrence

NCT00003472 2018-03-21

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma

Burzynski Research Institute

Phase 2 Terminated
13 enrolled 6 charts
CNS

Oligodendroglioma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡